An observational study in Frailty and Fall Risk, Fall Prevention, sponsored by University of Vigo. Recruiting at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Vigo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.
Among the 132 studies in Frailty with a site in Spain, this one is the 34th largest by planned enrollment of the 36 observational ones that give a count, is one of 21 that started in 2026, is one of 36 observational ones, reaches primary completion later than 35 of the 53 other live ones, and was the 128th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Granada · Sites in Spain
Ages 65+
Fundacion Miguel Servet · Sites in Spain
Ages 75+
Alberto Bermejo Franco · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · Sites in Spain
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is below the median of 225 across 495 observational studies indexed under Frailty.
Median enrollment 90 across the 96 interventional studies, 432 across the 36 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 132 have an industry lead sponsor. The 10 most frequent:
University of Vigo is the lead sponsor of 53 studies on the registry; 13 are open to participants now.
University of Vigo has 2 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
11 of the studies in Frailty with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04926597Philipp SchuetzEffect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery | 2026-12 |
| NCT06556537Universidad de ZaragozaEffects of Physical Exercise on Frailty, Mental and Physical Health of Older Adults in Rural Areas. | 2026-12-20 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT07643064Alberto Bermejo FrancoMulticomponent Exercise and Comprehensive Geriatric Assessment Program (FRAIL+AP) for Frail Older Adults in Primary Care | 2026-12-31 |
| NCT07848802University of VigoPhysical Function and Fall Risk in Older Adults in the Lalín Frailty Prevention Program | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Frailty with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study will describe changes in physical function and fall risk among adults aged 70 years or older who participate in the routine Frailty and Falls Prevention Program at the Centro Integral de Saúde de Lalín. Clinical assessments obtained before the program (T0) and at its completion (T1, approximately 8-12 weeks later) will be analyzed. The study does not assign treatment or change routine care.
Participants referred to the routine primary care physiotherapy program will be invited to provide written informed consent for the use of their clinical assessment data. The care program comprises 12 supervised weekly multicomponent exercise sessions, with individualized progression and home aerobic exercise advice. It includes strength, aerobic, flexibility, balance and functional exercises, and dual tasks. Physiotherapists will record baseline and end-of-program measures, attendance and care-related adverse events. The principal objective is to describe changes in Short Physical Performance Battery (SPPB) score and fall-risk indicators. Secondary objectives are to characterize the population, examine the association of attendance with functional change, and describe adverse events. The study is longitudinal and prospective, with within-person pre/post comparisons; exercise is delivered as routine care and is not assigned by the investigators for research. The target enrollment is 56, allowing for up to 15% loss from 47 evaluable participants calculated for the SPPB endpoint. No extra instrumented tests or procedures outside the described care are added for research.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Adults aged 70 years or older linked to the Centro Integral de Saúde de Lalín who enter its routine Frailty and Falls Prevention Program through usual care and can provide informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Routine multicomponent therapeutic exercise program; 12 supervised sessions, one per week, with individualized progression. Strength, aerobic, flexibility, balance, functional and dual-task components are described in the care protocol. Home aerobic activity is advised by the treating physiotherapist.
Change in Short Physical Performance Battery (SPPB) Total Score
Change in SPPB total score, a composite measure of lower-extremity function comprising standing balance, gait speed and chair rise. Score range: 0-12 points. Higher scores indicate better physical performance. Unit: points.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in Fall Risk Indicators
Change in the three protocol-defined yes/no indicators: a fall in the preceding year requiring healthcare, two or more falls in the preceding year, and clinically relevant gait impairment. Each indicator is recorded as No or Yes; no composite score or fixed numerical range is specified. A Yes response indicates the corresponding risk feature.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks); each assessment uses the protocol-defined recall or clinical assessment.
Change in Timed Up and Go Test Time
Time to stand, walk, turn, return and sit, recorded in seconds. Lower values indicate better mobility. Minimum: 0 seconds; no fixed maximum is specified in the protocol. The test is described as an alternative screening test in Section 4.4 and as a T0/T1 measure in the data collection form.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in FRAIL Scale Total Score
Change in FRAIL questionnaire total score. Score range: 0-5 points; higher scores indicate greater frailty. FRAIL Scale total score. The score ranges from 0 to 5 points, with higher scores indicating greater frailty. Unit: points.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in Number of Chronic Prescription Medications
Number of medicines prescribed chronically at each assessment. Unit: medication count; minimum 0, with no fixed maximum. Higher values indicate more chronic prescribed medicines, not necessarily a better or worse clinical outcome.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in 4 Meter Gait Speed
Usual gait speed over 4 meters, expressed in meters per second. Minimum 0 m/s; no fixed maximum is specified. Higher values indicate faster walking.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in 6 Minute Walk Test Performance
Performance on the 6-minute walk test. Total distance walked during the 6-Minute Walk Test. Unit: meters (m). Minimum possible value is 0 m; no fixed maximum is specified. Higher values indicate greater functional walking capacity.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks), when the 6-minute walk test is feasible.
Change in 2 Minute Step Test Performance
Performance on the 2-minute step test, used when the 6-minute walk test is not feasible because of insufficient space. Number of correctly completed steps during the 2-Minute Step Test. A step is counted when the designated knee reaches the target height defined midway between the patella and iliac crest. Unit: steps. Minimum possible value is 0 steps; no fixed maximum is specified. Higher values indicate greater aerobic endurance.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks), when the 6-minute walk test is not feasible.
Change in Arm Curl Test Performance
Performance on the arm curl test. Number of correctly completed arm-curl repetitions in 30 seconds using the protocol-defined external load. Unit: repetitions. Minimum possible value is 0 repetitions; no fixed maximum is specified. Higher values indicate greater upper-extremity functional strength/endurance.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in Functional Reach Test Performance
Performance on the Functional Reach Test. Maximum forward reach distance achieved while maintaining a fixed base of support during the Functional Reach Test. Unit: centimeters (cm). Higher values indicate greater functional reach and dynamic balance ability.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in Unipedal Stand Test Performance
Performance on the Unipedal Stand Test. Duration for which the participant maintains unipedal stance without external support with open eyes. Unit: seconds. Higher values indicate better static balance.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in Chair Sit and Reach Test Performance
Performance on the Chair Sit and Reach Test. Distance between the fingertips and the toes during the Chair Sit-and-Reach Test. Unit: centimeters (cm). A score of 0 cm indicates that the fingertips reach the toes; negative values indicate that the fingertips fall short of the toes, and positive values indicate that the fingertips extend beyond the toes. Higher values indicate greater lower-extremity flexibility.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Change in Back Scratch Test Performance
Performance on the Back Scratch Test. Distance between the middle fingertips during the Back Scratch Test. Unit: centimeters (cm). A score of 0 cm indicates that the fingertips touch; negative values indicate a gap between the fingertips, and positive values indicate overlap. Higher values indicate greater upper-body flexibility.
Time frame: Baseline (T0) and end of the care program (T1, 8-12 weeks).
Program Attendance
Number of supervised sessions attended out of 12 scheduled sessions; range 0-12 sessions. Higher values indicate greater attendance.
Time frame: Throughout the care program, from T0 to T1 (approximately 8-12 weeks).
Plan to share: Undecided — The research team is currently evaluating the possibility of sharing the data in accordance with the approved Ethics Committee protocol. According to the approval of the Ethics Committee and the informed consent document for participation in the research study, upon completion of the study, participants may choose whether their data should be deleted or retained in anonymized form for future research purposes. The possibility of sharing the data will therefore depend on each participant's choice. For participants who request deletion of their data, all corresponding data will be permanently destroyed once the study has been completed. Conversely, for participants who consent to the retention of their anonymized data for future research, the possibility of sharing the available anonymized data for subsequent research purposes may be considered, in accordance with the applicable ethical and regulatory requirements.
Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.
Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 4 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Vigo